John LaMattina joins Frequency Therapeutics in advisory role

Frequency Therapeutics has appointed John LaMattina as its senior advisor to the CEO in a role that will see him focus on assisting its development of a treatment for hearing loss, serving on the firm’s Scientific Advisory Board.

LaMattina was previously president of Pfizer’s Global Research and Development department and senior vice president and spent 30 years at the pharma company.

He said: “It is my pleasure to join Frequency Therapeutics as it begins clinical development of a treatment for hearing loss.

“The team has made remarkably rapid progress, and Frequency’s Progenitor Cell Activation platform presents an exceptional opportunity to develop a wide range of new-disease modifying therapies for hearing and other areas throughout the body.”

Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.

David Lucchino, president, co-founder and CEO of Frequences Therapeutics, said: “As a highly-regarded industry veteran, John brings us a wealth of knowledge and expertise.

"John has already begun to help us accelerate the development of our pipeline of product candidates for hearing restoration.”